Dolutegravir/Lamivudine Noninferior To Triple-Drug ART For Patients With Virologically Suppressed HIV, Study Finds

Infectious Disease Advisor (5/17, Nye) reported, “Dolutegravir/lamivudine (DTG/3TC) is noninferior to triple-drug antiretroviral therapy (ART) regimens for patients with virologically suppressed HIV infection, according to results of a study published in Open Forum Infectious Diseases.” In the study, “of patients receiving DTG-based ART at baseline, the rate of treatment failure at 1 year was 1.39% for those who switched to DTG/3TC and 0.80% for those in the control group (risk difference [RD], 0.59%). However, treatment failure rates in the intention-to-treat (ITT) population were higher among patients in the control group (12.50% vs 8.72%; RD, -3.78%).”